natgillin/translations-raw huggingface dataset:
På ovennævnte grundlag godtog CHMP, at resultaterne for YAZ Flex MB-regimet ekstrapoleres til det ansøgte dosisregime for Yvidually. 
Based on the above, the CHMP agreed that the results of the YAZ Flex MB regimen could be extrapolated to the proposed dosing regimen of Yvidually.
YAZ Flex MB hos 880 kvinder i 2 år (antikonceptiv virkning + blødning) 
YAZ flex MB in 880 women for 2 years (contraceptive efficacy + bleeding)
Uanset blødning og/eller pletblødning kunne kvinden vælge at planlægge bortfaldsblødningen (dvs. det 4-dages tabletfri interval) til et vilkårligt tidspunkt mellem dag 25 og 120 i behandlingscyklussen. 
Irrespective of bleeding and/or spotting, women are allowed to schedule their withdrawal bleeding (i.e. the 4-day tablet-free interval) at any time between days 25 and 120 of the treatment cycle.
I disse undersøgelser vurderedes den antikonceptive virkning, dvs. antallet af utilsigtede graviditeter, Pearl-indeks (PI) (beregnet som graviditetsrate i populationen divideret med 100 års brugereksponering) og den kumulative graviditetsrate i undersøgelsernes YAZ Flex MB-arme samt blødningsmønster og cykluskontrolparametre i alle behandlingsarme i begge undersøgelser. 
These studies evaluated contraceptive efficacy, i.e. the number of unintended pregnancies, PI (calculated as the pregnancy rate in population divided by 100 years of user exposure) and cumulative pregnancy rate in the YAZ Flex MB arms, as well as bleeding pattern and cycle control parameters in all treatment arms of both studies.
Under den indledende decentrale procedure blev der alligevel anmodet om en beregning af Pearl-indeks for Stop & Go-armen, YAZ fixed extended-armen og YAZ 24+4-armen, jf. nedenstående tabel: 
Notwithstanding, during the initial DCP procedure a calculation of the PI was requested for the Stop & Go arm, YAZ fixed extended arm, and YAZ 24+4 arm, see table below:
På dag 25-120 kan kvinden vælge at tage et 4-dages tabletfrit interval (hun planlægger en bortfaldsblødning) på ethvert tidspunkt, der passer hende, og uafhængigt af blødning. 
During days 25- 120, the woman may decide to take a 4-day tablet-free interval (she schedules a withdrawal bleeding) at any time that suits her best, and irrespective of bleeding.
Dertil kommer, at der ifølge ansøgerens redegørelse kun blev iagttaget små forskelle i antallet af cyklusser (dvs. 4-dages pauser) og gennemsnitlig cykluslængde (antal dage med uafbrudt tabletindtag) mellem YAZ Flex MB-varianten og YAZ Stop & Go-regimet (se tabellerne nedenfor). 
Additionally, as presented by the applicant, only slight differences in the number of cycles (i.e 4-day breaks) and mean cycle length (number of days of continuous intake of tablets) between YAZ Flex MB variant and the YAZ Stop & Go regimen were observed (see tables below).
Det blev imidlertid drøftet og bemærket, at det høje PI i YAZ Stop & Go-armen af USA-undersøgelsen A48294 var baseret på kun 170 kvindeårs (WY) anvendelse, hvilket medførte et bredt 95 % sikkerhedsinterval: 3,52 (95 % SI: [1,29; 7,67]). 
However it was discussed and noted that the high PI in YAZ Stop & Go arm of USstudy A48294 was based on only 170 Woman Years (WY) of use, resulting in a wide 95% CI; 3.52 (95% CIs: 1.29 - 7.67).
Virkningen af YAZ Stop & Go-regimet blev yderligere dokumenteret ved en interimanalyse af den supplerende igangværende europæiske, randomiserede, åbne multicenterundersøgelse 14701, hvor dispenseren anvendes med det ansøgte doseringsregime for Yvidually. 
Further evidence for the efficacy of the YAZ Stop & Go regimen was obtained when the results of an interim analysis of an additional ongoing European multi-center randomised open study 14701, using the dispenser with the proposed dosing regimen of Yvidually became available.
Pearlindeks 95 % SI 1,29-7,67 
Pearl Index 95% CI 1.29 - 7.67 0.00 - 3.47 0.13 - 3.85 0.15 - 4.35
PÅ dag 25-120 kan hun planlægge et 4-dages tabletfrit interval (fremkaldelse af bortfaldsblødning), hvis der forekommer 3 på hinanden følgende dage med blødning. 
During days 25- 120, she may schedule a 4-day tablet-free interval (induction of withdrawal bleeding) in the event of 3 consecutive days of bleeding.
29, stk. 4, i Rådets direktiv 2001/83/EF 
• The Committee considered the notification of the referral triggered by France under Article 29(4) of Council Directive 2001/83/EC.
Det udvidede dosisregime for Yvidually er udviklet på grundlag af det markedsførte kombinerede orale antikonceptionspræparat Yaz 24+4 til kvinder, der ønsker at udsætte bortfaldsblødningen ved at forlænge cyklus i indtil 120 dage. 
The extended dose regimen of Yvidually has been developed based on the marketed combined oral contraceptive Yaz 24+4 for women who want to postpone the withdrawal bleeding by extending the intake cycle up to 120 days.
Yaz Stop & Go hos 200 kvinder i 1 år (blødning) Yaz 24+4 hos 200 kvinder i 1 år (blødning) 
YAZ Stop & Go in 200 women for 1 year (bleeding) YAZ 24+4 in 200 women for 1 year (bleeding)
Yaz fixed extended hos 200 kvinder i 1 år (blødning) Yaz 24+4 hos 200 kvinder i 1 år (blødning) 
YAZ fixed extended in 200 women for 1 year (bleeding) YAZ 24+4 in 200 women for 1 year (bleeding)
Eksponeringen var her kun 357 kvindeår (wy), men det beregnede PI var 0 med en øvre 95 % sikkerhedsgrænse på 1,0 og opfylder således kravene til nøjagtighed i CHMP's “Guideline on Clinical Investigation of Steroid Contraceptives in Women” (EMEA/CPMP/EWP/519/98 Rev 1). 
The exposure was limited to 357 women-years (wy), but the calculated PI was 0, with an upper limit of the 95% confidence interval of 1.0 fulfilling the requirements of precision of the CHMP Guideline on Clinical Investigation of Steroid Contraceptives in Women (EMEA/CPMP/EWP/519/98 Rev 1).
På ovennævnte grundlag konkluderedes det, at den antikonceptive virkning er tilstrækkeligt godtgjort med YAZ Flex MB-varianten af regimet (Pearl-indeks 0,63, 95 % øvre sikkerhedsgrænse 1,24), som anses for repræsentativ for det ansøgte doseringsregime for Yvidually hvad angår antikonceptiv virkning. 
Based on the above, it was concluded that contraceptive efficacy had been sufficiently demonstrated with the YAZ Flex MB variant of the regimen (Pearl Index of 0.63, upper limit of 95% CI 1.24), which is considered representative of the proposed dosing regimen of Yvidually with regard to contraceptive efficacy.
• udvalget fandt den overordnede virkning tilfredsstillende godtgjort med de forelagte undersøgelser, 
• The Committee considered that the overall efficacy has been sufficiently proven by the data presented, in particular the EU/Canada study.
Desuden blev der udført en tredje undersøgelse (A47505) hos kvinder med moderat til svær primær dysmenorré. 
Additionally, a third study (A47505) was conducted in women with moderate to severe primary dysmenorrhea and is presented as a supportive clinical trial regarding information on bleeding pattern during use of the extended dose regimen.
Sammenfattende viser oplysningerne, at produktet i forhold til YAZ 24+4 giver færre bortfaldsepisoder og samlet færre blødningsdage på 1 år, hvilket er hensigten. 
In summary, the data have demonstrated that compared to YAZ 24+4, the number of withdrawal episodes decreases as well as the total number of bleeding days over a period of 1 year, which is the aim of this product.
Dokumentationen bygger primært på de tilfredsstillende værdier af Pearl-indekset, der blev opnået i EU-/Canada-undersøgelsen, som omfattede en europæisk population og tillod et 4-dages tabletfrit interval i tilfælde af 3 på hinanden følgende dage med blødning og/eller pletblødning (Flex MB-regime). 
Evidence is primarily based on the adequate pearl indices obtained on EU/Canada study including an European population that allowed a 4-day tablet-free interval in case of 3 consecutive days of bleeding and/or spotting (Flex MB regimen).
Følgende dosisregimer blevet undersøgt i de to 3-armede kliniske fase III-hovedundersøgelser (undersøgelse A47505 blev ikke vurderet, da YAZ FlexMB i denne var bestemt til behandling af dysmenorré i stedet for som antikonceptivum): Yaz Flex Managed Bleeding (Yaz FlexMB)-regime: Hver cyklus består af 120 dages tilsigtet behandling efterfulgt af et 4 dages tabletfrit interval til fremkaldelse af bortfaldsblødning. 
This study A47505 was not assessed as in this study YAZ FlexMB was intended for the treatment of dysmenorrhoea instead of contraceptive efficacy) The following dose regimens were studied in the two pivotal 3-armed clinical Phase III studies: YAZ Flex Managed Bleeding (YAZ FlexMB) regimen; each cycle comprises 120 days of intended treatment followed by a 4-day tablet-free interval to induce withdrawal bleeding.
Hovedundersøgelserne skal være mindst så store, at det totale Pearl-indeks (antal graviditeter pr. 100 kvindeår) kan estimeres med et 95 % tosidet sikkerhedsinterval, hvis øvre grænse ikke overstiger punktestimatet med mere end 1. 
The key studies should be at least large enough to give the overall PI (number of pregnancies per 100 woman years) with a two-sided 95% confidence interval such that the difference between the upper limit of the 95% confidence interval and the point estimate does not exceed 1.
Desuden aftog det årlige antal blødningsdage fra 66 (YAZ 24+4) til 41-47 dage (YAZ Stop & Go og YAZ Flex MB). 
Further, the total number of bleeding days per year decreased from 66 (YAZ 24+4) to 41-47 days (YAZ Stop & Go and YAZ Flex MB).
Med væsentligt færre 4-dages tabletfri intervaller og længere perioder med aktiv behandling i begge varianter vil virkningen desuden højst sandsynligt være mindst lige så god som påvist for YAZ 24+4. 
Moreover, with considerably less 4-day tablet-free intervals and longer periods of active treatment in both variants, it is highly likely that the efficacy will be at least as good as established for YAZ 24+4.
Med betydeligt færre tabletfrie intervaller og længere perioder med aktiv behandling i begge varianter vil virkningen desuden være mindst lige så god som dokumenteret for det godkendte YAZ 24+4. 
Moreover, with considerably less tablet-free intervals and longer periods of active treatment in both variants, efficacy will be at least as good as established for the currently authorised YAZ 24+4.
YAZ Flex MB hos 1 400 kvinder i 1 år (antikonceptiv virkning + blødning) 
YAZ Flex MB in 1400 women for 1 year (contraceptive efficacy + bleeding)
På dag 25-120 kan kvinden beslutte at tage tabletterne uafbrudt i op til højst 120 dage. 
During days 25-120, the woman can decide to take tablets continuously up to a maximum of
Ved betragtning af resultaterne af Yaz Stop and Go-regimet blev det bemærket, at Pearl-indeks (PI) for Yaz Stop and Go-regimet var højere (3,52 med 95 % SI [1,29; 7,67]) end PI for Yaz Flex MBregimet i samme undersøgelse (1,67 med 95 % øvre sikkerhedsgrænse 2,67). 
When looking at the results of the YAZ Stop and Go regimen, it was noted that the PI was higher (3.52; 95% CI; 1.29 - 7.67) compared to the YAZ Flex MB regimen in the same study (1.67 95% CI; upper limit 2.67).
Grunden til pausen (optræden af blødning eller kvindens eget valg) har ingen indflydelse på den antikonceptive virkning, så længe de generelle regler for indtag er overholdt, dvs. regelmæssigt uafbrudt dagligt tabletindtag i mindst 24 dage og tabletfrie intervaller på højst 4 dage mellem cyklusserne med tabletindtag. 
The reason for the break (bleeding occurrence or woman's own choice) will not influence the contraceptive efficacy, as long as the general rules of intake will be adhered to, that is regular uninterrupted daily tablet intake for at least 24 days and tablet-free intervals of a maximum of 4 days between intake cycles.
Der var ingen væsentlige forskelle i cyklusantal eller gennemsnitlig cykluslængde, når der blev givet mulighed for et 4-dages tabletfrit interval uafhængigt af blødning og/eller pletblødning (Stop & Go-regime). 
No significant differences in number of cycles and mean cycle length were observed when a 4-day tablet-free interval was allowed irrespective of bleeding and/or spotting (Stop & Go regimen).
Dokumentationen bygger primært på det opnåede Pearl-indeks i EU/Canada-undersøgelsen, der tillod et 4-dages tabletfrit interval i tilfælde af 3 på hinanden følgende dage med blødning og/eller pletblødning (Flex MB-regime). 
Evidence is primarily based on the pearl indices obtained in an EU/Canada study that allowed a 4-day tablet-free interval in case of 3 consecutive days of bleeding and/or spotting (Flex MB regimen).
Sædvanligvis har årsagen til pausen (optræden af blødning eller kvindens eget valg) ingen betydning for den antikonceptive virkning, så længe de generelle regler for indtag overholdes, dvs. regelmæssig uafbrudt dagligt tabletindtag i mindst 24 dage og tabletfrie intervaller på højst 4 dage mellem cyklusser med tabletindtag. 
In general, the reason for the break (bleeding occurrence or woman's own choice) will not influence the contraceptive efficacy, as long as the general rules of intake will be adhered to, that is regular uninterrupted daily tablet intake for at least 24 days and tablet-free intervals of a maximum of 4 days between intake cycles.
Til bestemmelse af den antikonceptive virkning anvendtes Pearl-indekset (PI), beregnet som graviditetsrate i undersøgelsens population divideret med 100 års brugereksponering. 
The Pearl Index (PI) calculated as the pregnancy rate in the study population divided by 100 years of user exposure, was used to assess contraceptive efficacy.
På den anden side aftog antallet af bortfaldsblødninger fra 12 gange årligt (YAZ 24+4) til 4,6 og 4,5 gange årligt (YAZ Stop & Go og YAZ Flex MB). 
On the other hand, the number of withdrawal bleedings decreased from 12 times/year (YAZ 24+4) to 4.6 and 4.5 times/year (YAZ Stop & Go and YAZ Flex MB).
I den konventionelle YAZ 24+4-arm er der 10,1 tabletfrie 4-dages intervaller i løbet af et år, da de tabletfrie intervaller er obligatoriske (dvs. 24 dages tabletindtag efterfulgt af en 4dages pause (YAZ 24+4)). 
In the conventional YAZ 24+4 arm, the number of 4-day tablet-free intervals within one year is 10.1, as the tablet-free intervals are mandatory (i.e. 24 days of tablet intake followed by a 4 day break (YAZ 24+4)), versus 4.2 and 4.6 breaks for YAZ Flex MB and YAZ Stop & Go respectively.
Den antikonceptive virkning af Yvidually blev yderligere dokumenteret ved interimanalyse af en igangværende undersøgelse med Yvidually, hvor det beregnede PI var 0 med en øvre 95 % sikkerhedsgrænse på 1,0, hvilket anses for konklusivt hvad angår nøjagtigheden af Pearl-indekset. 
Further supportive evidence of adequate contraceptive efficacy of Yvidually was obtained from the interim analysis of an ongoing trial with Yvidually where the calculated PI was 0 with an upper limit of the 95% confidence interval of 1.0, which is considered conclusive in terms of precision of the Pearl Index.
n 
Whereas
Formålet med YAZ Stop & Go-armen (kun i USA-undersøgelsen), YAZ fixed extended-armen (i EU/Canada-undersøgelsen) og YAZ 24+4-armen (begge undersøgelser) i de to undersøgelser var at sammenligne forskellige blødningsmønstre. 
The YAZ Stop & Go arm (in the US study only), the YAZ fixed extended arm (in the EU/Canada study) and the YAZ 24+4 arm (both studies) were included in the two studies to compare different bleeding patterns.
Dispenseren er en integreret del af Yvidually og skal sikre, at tabletterne tages i henhold til det ansøgte dosisregime. 
The dispenser which has been designed to be an integral part of Yvidually in order to deliver tablets in line with the proposed dose regimen, has not been used in the pivotal studies.
Som konklusion er den antikonceptive virkning af Yvidually tilfredsstillende godtgjort for det ansøgte doseringsregime for Yvidually, hvor kvinden selv kan vælge at tage et 4-dages tabletfrit interval eller ikke under den fleksible fase. 
It is concluded that contraceptive efficacy of Yvidually has been sufficiently demonstrated for the proposed dosing regimen of Yvidually that allows the woman to decide herself to take a 4-day tablet-free interval or not during the flexible phase.
Udsættelse af en bortfaldsblødning medfører højere risiko for intracyklisk blødning hos de fleste kvinder. 
It is known and described in the SmPCs of all COCs that postponing a withdrawal bleed will introduce higher risk of intracyclic bleeding in most women.
YAZ Stop & Go-armen (kun i USA-undersøgelsen), YAZ fixed extended-armen (i EU-/Canadaundersøgelsen) og YAZ 24+4-armen (i begge undersøgelser) havde til formål at sammenligne forskellige blødningsmønstre i de to undersøgelser, men havde ikke styrke til at vurdere den antikonceptive virkning. 
The YAZ Stop & Go arm (in the US study only), the YAZ fixed extended arm (in the EU/Canada study) and the YAZ 24+4 arm (in both studies) were included in the two studies to compare different bleeding patterns, but were not powered to assess contraceptive efficacy.
Den antikonceptive virkning blev dokumenteret for Yaz Flex MB-regimet i EU-/Canadahovedundersøgelsen A40196, hvor Pearl-indeks (PI) var 0,63 med en øvre 95 % sikkerhedsgrænse på 1,24 hos kvinder mellem 18 og 35 år. 
The contraceptive efficacy was demonstrated for the YAZ Flex MB regimen in the pivotal EU/Canada study A40196, by a PI of 0.63 with a corresponding upper limit of the 95% confidence interval of 1.24 in women between 18 and 35 years of age, and a PI for method failure (PIA adjusted) of 0.59 (upper limit 95% confidence interval 1.22).
Udsættelse af en bortfaldsblødning giver højere risiko for intracyklisk blødning hos de fleste kvinder, således som det allerede kendes fra de nuværende kombinerede orale antikonceptionsmidler. 
Postponing a withdrawal bleed will introduce higher risk of intracyclic bleeding in most women, as is already known from current COCs, but the data available do not indicate that the noted bleeding patterns of Yvidually had a negative impact on tolerability of the women.
Dosisanbefalinger 
Dose recommendations
Sammenfattende er Yvidually udviklet til kvinder, som ved at forlænge indtagscyklus i indtil 120 dage ønsker at udsætte den månedlige bortfaldsblødning, der optræder med det markedsførte kombinerede orale antikonceptivum YAZ 24+4. 
In summary, Yvidually has been developed for women who want to postpone the monthly withdrawal bleeding, occurring with the marketed combined oral contraceptive YAZ 24+4, by extending the intake cycle up to 120 days.
I YAZ Flex MB-regimet svarede antallet af dage med intracyklisk blødning (5 dage/år) til det konventionelle YAZ 24+4-doseringsregime (6 dage/år), hvorimod der var flere i YAZ Stop & Go (14,8 dage/år). 
Compared to the conventional YAZ 24+4 dosing regimen (6 days/year), the number of days of intracyclic bleeding was comparable in the YAZ Flex MB regimen (5 days/year), but more frequent in the YAZ Stop & Go (14.8 days/year).
Yvidually er udviklet til kvinder, der ved at forlænge indtagscyklus i indtil 120 dage ønsker at udsætte den månedlige bortfaldsblødning, som optræder med det markedsførte kombinerede orale antikonceptionsmiddel YAZ 24+4. 
Yvidually has been developed for women who want to postpone the monthly withdrawal bleeding, occurring with the marketed combined oral contraceptive YAZ 24+4 by extending the intake cycle up to 120 days.
Der er kun små forskelle mellem YAZ Flex MB og YAZ Stop & Go i det gennemsnitlige antal cyklusser (4,2 mod 4,6 pauser/år) og cykluslængden (73-78,2 mod 70,4 dage med uafbrudt tabletindtagelse pr. behandlingscyklus). 
It is not expected that these slight differences in mean number of cycles (4.2 versus 4.6 breaks/year) and cycle length (73-78.2 versus 70.4 days of continuous tablet intake per treatment cycle) between YAZ Flex MB and YAZ Stop & Go will lead to a relevant difference in contraceptive efficacy.
Den ene behandlingsarm indgik både i EU-/Canada-undersøgelsen og i USAundersøgelsen og blev anset for repræsentativ for den antikonceptive virkning af Yvidually og anvendt til sammenligning med blødningsmønstret for YAZ 24+4 og de øvrige dosisregimer. 
This treatment arm was included in both EU/Canada study and the US study and considered to be representative for the contraceptive efficacy of Yividually, as well as a comparison of the bleeding pattern with the bleeding pattern of YAZ 24+4 and other dose regimens; YAZ Stop & Go regimen; each cycle comprises 120 days of intended treatment followed by a 4day tablet-free interval to induce withdrawal bleeding.
Det er tilfredsstillende godtgjort, at der er færre bortfaldsepisoder og lavere samlet antal blødningsdage i løbet af et år end med YAZ 24+4 (konventionelt regime), hvilket er hensigten med produktet. 
The data have adequately demonstrated that compared to YAZ 24+4 (conventional regimen), the number of withdrawal episodes decreases as well as the total number of bleeding days over a period of 1 year, which is the aim of this product.
Også for andre kombinerede antikonceptionsmidler er fundet højere værdier af Pearl-indeks i undersøgelser udført i USA, formodentlig som følge af kompliansproblemer. 
Higher PIs were obtained in the other pivotal study A48294 that was carried out in the US. Higher PIs have also been observed for other COCs in studies performed in the US, which is probably related to problems with compliance.
YAZ 24+4 (YAZ)-regime: 24 dages uafbrudt tabletindtagelse efterfulgt af et 4-dages tabletfrit interval (et regime, der er godkendt i Europa) indgik i begge undersøgelser for at sammenligne blødningsmønstret. 
This arm was included in the EU/Canada study in order to compare with bleeding patterns of the other treatment arms; YAZ 24+4 (YAZ) regimen; 24 days of continuous tablet-taking followed by a 4-day tablet-free interval (regimen authorised in Europe) included in both studies in order to compare bleeding patterns; Except for the YAZ fixed extended regimen, the minimum treatment period between tablet-free intervals (i.e. minimum cycle length) in each regimen was 24 days (to maintain contraceptive efficacy).
navnlig EU-/Canada-undersøgelsen, og udvalget anså benefit/risk-forholdet for Yvidually og tilknyt tede navne til den ansøgte indikation og det udvidede doseringsregime for at være positivt anbefalede CHMP udstedelse af markedsføringstilladelse på de anbefalede betingelser vedrørende sikker og effektiv anvendelse af lægemidlet som angivet i bilag IV. Produktresuméet, etiketteringen og indlægssedlen er uændrede svarende til de endelige versioner, der er fastlagt ved behandlingen i koordinationsgruppen som anført i bilag III for Yvidually og tilknyttede navne (se bilag I). 
The summary of product characteristics, labelling and package leaflet remain as per the final versions achieved during the Coordination group procedure as mentioned in Annex III for Yvidually and associated names (see Annex I).
Denne arm indgik i USA-undersøgelsen for at sammenligne blødningsmønsteret med blødningsmønsteret for YAZ 24+4 og YAZ FlexMB. 
This arm was included in the US study for comparison of bleeding pattern with bleeding patterns of YAZ 24+4 and YAZ FlexMB; YAZ fixed extended regimen; 120 days of continuous tablet-taking (without any break) followed by a 4-day tablet-free interval.
Lægen vil afgøre hvilken styrke, der er bedst for Dem. 
Your doctor will decide which strength is best for you.
Data fra fire større afprøvninger bliver vist her. 
Data from four major trials are presented here.
Dato for fornyelse: 20/11/2006 
Date of renewal: 20/11/2006
Spørg desuden Deres læge til råds om andre passende solbeskyttelsesmetoder. 
In addition, ask your doctor for advice on other appropriate sun protection methods.
DATO FOR ÆNDRING AF TEKSTEN {DD/MM/ ÅÅÅÅ } 
DATE OF REVISION OF THE TEXT {DD/MM/YYYY}
Der er ikke blevet foretaget specielle studier med ældre patienter. 
Specific studies have not been conducted in elderly patients.
DATO FOR FØRSTE TILLADELSE/FORNYELSE AF TILLADELSEN Dato for første tilladelse: 28/02/2002 
DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 28/02/2002
Rosacea og rosacea-lignende dermatitis er også blevet rapporteret. 
Rosacea and rosacea-like dermatitis have also been reported.
Hvad Protopy indeholder 
What Protopy contains
Det er ikke sikkert, at alle pakningsstørrelser markedsføres. 
Not all pack sizes may be marketed.